Objective: To study the effects of consuming isoflavone aglycone-enriched soymilk fermented by bifidobacteria on urinary excretion of equol with respect to fermentation, daidzein dose, supplementation duration and background diet. Design: Double-blind crossover pilot study comprising three 14-day supplementation periods separated by a washout. Setting: Victoria University, Melbourne, Australia. Subjects: Sixteen postmenopausal women. Intervention: Subjects randomized into two groups consuming either fermented (FS) or non-fermented soymilk (NFS), ingested three daily dosages of daidzein via soymilk and collected pooled urine specimens. Daidzein and equol were quantified using high-performance liquid chromatography. Results: After 14-days supplementation six women (38%) excreted equol (41 mmol equol/day), including four from the FS group, two of whom were classified as non-producers at day 4. Bifidobacteria ingestion, composition of daidzein and its glucosides, and carbohydrate intake appeared to influence equol formation among equol producers. Conclusions: Pilot-study group mean urinary equol excretion results provided insufficient evidence (P40.05) that FS consumption instigates equol production in women predetermined as non-producers.
Introduction
Equol is the exclusive product of the intestinal bacterial metabolism of daidzein and its conjugates, found abundantly in soybeans. The oestrogenic and antioxidant effects of equol are greater than daidzein (Arora et al., 1998; Morito et al., 2001) . Maximal clinical responses to soy protein have been observed in people able to produce equol (Setchell et al., 2002) . However, only 30-40% of adults synthesize equol after ingesting soyfoods (Setchell et al., 2003) . The reason for these two distinct sub-populations is unclear, but may be due to intestinal microbial composition. Probiotic bifidobacteria are predominant microflora in the ileum and colon (Orrhage and Nord, 2000) , the most probable site of equol synthesis (Setchell et al., 2003) . Bifidobacterium possess complex enzyme systems allowing them to metabolize organic compounds (Ballongue, 1993) . Bifidobacterium animalis Bb-12 (BB12) was shown to biotransform daidzein into equol when grown in soymilk (Tsangalis et al., 2002) . The aims of this pilot study were to examine the effects of fermentation (by bifidobacteria), dose of daidzein, duration of supplementation and background diet on the urinary excretion of equol by postmenopausal women consuming soymilk.
Subjects and methods
Sixteen healthy postmenopausal women recruited from the Melbourne metropolitan area (Australians of western European descent) were randomly allocated to one of two groups to consume either 200-ml fermented or non-fermented soymilk (NFS) per day. The mean (7s.d.) age of women in the fermented soymilk (FS) and NFS group was 52.5 (73.1) and 55.6 (75.1) years, respectively. The study was approved by the Human Research Ethics Committee of Victoria University (Melbourne, Australia) and consisted of a doubleblind crossover design involving three 14-day supplementation periods separated by a 14-day washout. Subjects ingested three daily doses of daidzein. Four 24-h pooled urine specimens were collected per supplementation period (baseline, days 4, 13 and 14) and processed as per (Tsangalis et al., 2005) . Each participant consumed a restricted selfselected diet and provided a weighed food record.
Three FS and NFS containing 20 (SPI/SG20), 40 (SPI/SG40) or 80 (SPI/SG80) mg isoflavone/200 ml were manufactured and packaged as described earlier (Tsangalis et al., 2005) . Soymilk from each batch was analysed for daidzein and its glucosides using high-performance liquid chromatography (HPLC) (Tsangalis et al., 2005) . Fermented soymilk contained approximately 10 8 viable cells of BB12 per millilitre. Urinary equol was extracted and analysed using a method involving b-glucuronidase/sulphatase deconjugation, previously used to quantify urinary daidzein (Tsangalis et al., 2005) . However, HPLC conditions for equol were as per Xu et al., (1994) , with the ultraviolet-visible detector set at 282 nm. To find significant differences in the urinary excretion of equol between groups, doses of daidzein and supplementation days, the data were analysed with the non-parametric Wilcoxon/Kruskal-Wallis test using JMP statistical software (SAS Institute, Cary, NC, USA). Probabilities of 0.05 or less were considered statistically significant. Replicates with undetectable levels of equol were included in statistical analyses and assigned the detection limit of the assay (0.41 mmol/l).
Results and discussion
SPI/SG20, SPI/SG40 and SPI/SG80 contained 22.6, 37.4 and 67.3 mmol daidzein per 200 ml, respectively. Non-fermented SPI/SG20, SPI/SG40 and SPI/SG80 comprised 16, 13 and 9% aglycone, respectively, with their fermented counterparts containing 73, 63 and 43% aglycone. We classified a subject as an equol producer if their urinary excretion of equol was 41 mmol/day, as per Rowland et al. (2000) . Mean urinary excretion of equol by each subject is shown in Table 1 . Two women from both the NFS and FS group were classified as equol producers. Subject 4 of the NFS group and subject 6 of the FS group excreted greater levels of equol during supplementation of SPI/SG20 (P ¼ 0.061) and Equol excretion by postmenopausal women D Tsangalis et al SPI/SG40 (P ¼ 0.061), respectively. For subject 8 of the FS group and subject 1 of the NFS group, 67.3 mmol daidzein/ day appeared to stimulate equol production, regardless of whether daidzein was found in an aglycone-or glucosiderich configuration. Mean urinary excretion of equol by the FS and NFS group is shown in Figure 1 . There were no significant differences between the groups at any of the doses to indicate that the consumption of soymilk fermented by bifidobacteria enhanced equol production (P40.05). Nevertheless, there was a trend towards a positive correlation between urinary equol excretion and dose of daidzein, with greater excretion shown during supplementation of SPI/SG80 (P40.05). Earlier, we reported that the absolute urinary excretion of daidzein was highest during supplementation of SPI/SG80, even though it was associated with the lowest percentage recovery of daidzein (Tsangalis et al., 2005) . Therefore, only a limited amount of a high dose of daidzein may be absorbed in the proximal intestinal tract, with the remaining fraction passing into the ileum and colon where there are greater bacterial populations that could biotransform daidzein into equol. This may be the reason for increased equol excretion during ingestion of SPI/SG80. Lu and Anderson (1998) reported that some women who were initially unable to metabolize daidzein into equol, appeared to develop this ability over a month of daily soy ingestion. Thus, we allocated pooled urine collection to days 4, 13 and 14 of supplementation for the intestinal microflora to adapt to the ingestion of soymilk, and for the intestinal microbial balance of women in the FS group to change as a result of the consumption of viable BB12. Figure 1 shows that in most cases mean urinary equol excretion for the FS and NFS group tended to be greater after 13 and 14 days of supplementation compared to day 4 (P40.05). Subjects 1 and 2 of the FS group did not excrete detectable levels of equol on day 4. However, on days 13 and 14, they excreted 41 mmol equol at each dose of daidzein, classifying them both as equol producers. Consequently, the FS group comprised four equol producers. In all, six women (38% of total participants) excreted 41 mmol equol/day, two of whom exhibited a delayed response (25% of the FS group). This contrasts with the findings of Akaza et al. (2004) , who examined the stability of equol-producing status in freeliving populations in the absence of an intervention and found that only 15% of subjects changed their equolproducing status over a period of 569 days. Therefore, our observation that two of the eight subjects consuming FS changed their equol-producing status during each 14-day supplementation period, in comparison to none of the eight subjects in the NFS group, warrants further investigation. Rowland et al. (2000) reported that a high intake of carbohydrate and fibre was associated with enhanced equol excretion in women. In the FS group, subjects 1 and 2 (delayed equol producers) had the highest intakes of carbohydrate and fibre during each supplementation period. Furthermore, there may have been a synergistic relationship between the ingestion of viable BB12 and greater total intake of carbohydrate and fibre that stimulated the metabolic activity of intestinal bacteria in subjects 1 and 2 of the FS group, enhancing equol excretion to 41 mmol on days 13 and 14.
In summary, although subject numbers in this novel pilot study preclude definitive conclusions, a higher dose of daidzein was apparently associated with increased urinary excretion of equol in postmenopausal women, whether consumed via FS or NFS. Equol excretion tended to be higher after 13 and 14 days of soymilk supplementation, possibly enhanced by a background diet rich in carbohydrate and fibre. Our preliminary findings therefore support the need for a clinical trial using a large number of equol nonproducers, a supplementation period of 6-12 months, including analysis of blood, urine and faeces to ascertain whether prolonged consumption of fermented soymilk containing viable bifidobacteria instigates equol production in women. Equol not detected at baseline (detection limit of 0.41 mmol/l). Equol levels excreted at days 4, 13 and 14 were analysed using the non-parametric Wilcoxon/Kruskal-Wallis test of rank sums. No significant differences were found (P40.05).
